First market launch of the adrenaline nasal spray, EURneffy®, for treatment of adults and children in Germany

Core Insights - ALK has launched EURneffy 2 mg, the first adrenaline nasal spray for emergency treatment of anaphylaxis in Germany, marking a significant milestone for patients with life-threatening allergic reactions [1][2] - The product features a needle-free design, longer shelf life of 30 months, and superior temperature stability compared to existing adrenaline auto-injectors, aiming to improve emergency treatment outcomes [2] - The EU approval was based on clinical data from over 700 participants, with no serious adverse events reported, and a 1 mg dosage for patients weighing 15-30 kg is under review, expected to complete in 2026 [2] Company Developments - ALK entered a strategic license agreement with ARS Pharmaceuticals in November 2024, granting exclusive global rights to commercialize neffy, excluding certain countries, and extended the partnership to include a co-promotion agreement in the USA in May 2025 [4] - The market launch of EURneffy does not impact ALK's financial guidance for 2025 [4] Industry Context - Anaphylaxis affects up to eight out of every 100,000 people annually in Europe, with one in 300 experiencing it at some point in their lives, highlighting the need for effective emergency treatments [3]